Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORIUM: Pulse corticosteroids and/or IVIG for fulminant myocarditis
2023-506599-28-01Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexamethasone and subcuvia in Fulminant myocarditis (FM) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Hierarchical composite outcome at day 28. Planned start Jan 2025; status: authorised.
02
Drugs
dexamethasonesubcuvia
03
Conditions
Fulminant myocarditis (FM)
Beyond the preview
Go deeper on 2023-506599-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506599-28-01.